Home
Drugs
Cytarabine
Clinical Trials

Clinical Trials Related to Cytarabine

Related studies linked through entity extraction aliases.

Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Status: UNKNOWN
Phase: NA

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Status: UNKNOWN
Phase: PHASE2

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Status: TERMINATED
Phase: PHASE1/PHASE2

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Status: TERMINATED
Phase: PHASE3

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Status: NOT_YET_RECRUITING
Phase: PHASE3

Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

Status: TERMINATED
Phase: PHASE2

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Status: RECRUITING
Phase: PHASE2

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Status: COMPLETED
Phase: PHASE1/PHASE2

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Status: RECRUITING
Phase: PHASE1/PHASE2

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Status: TERMINATED
Phase: PHASE2

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Status: TERMINATED
Phase: PHASE3

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Status: TERMINATED
Phase: PHASE1/PHASE2

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Status: UNKNOWN
Phase: PHASE2

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Status: COMPLETED
Phase: PHASE1/PHASE2

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Status: RECRUITING
Phase: PHASE1

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Status: RECRUITING
Phase: PHASE2